Nyhetssvepet onsdag 13 september - BioStock - Connecting Innovation and Capital
| SCOL Stock | SEK 0.06 0.01 9.70% |
Slightly above 62% of Scandion Oncology's investor base is looking to short. The analysis of current outlook of investing in Scandion Oncology AS suggests that many traders are alarmed regarding Scandion Oncology's prospects. Scandion Oncology's investing sentiment can be driven by a variety of factors including economic data, Scandion Oncology's earnings reports, geopolitical events, and overall market trends.
Scandion |
Nyhetssvepet onsdag 13 september BioStock - Connecting Innovation and Capital
Read at news.google.com
 |
Scandion Oncology Fundamental Analysis
We analyze Scandion Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scandion Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scandion Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Scandion Oncology is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Scandion Oncology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Scandion Oncology stock to make a market-neutral strategy. Peer analysis of Scandion Oncology could also be used in its relative valuation, which is a method of valuing Scandion Oncology by comparing valuation metrics with similar companies.
Peers
Scandion Oncology Related Equities
| ONCO | Oncopeptides | 9.72 | ||||
| HNSA | Hansa Biopharma | 3.73 | ||||
| EXPRS2 | ExpreS2ion Biotech | 2.00 | ||||
| FLUO | Fluoguide | 1.11 | ||||
| SANION | Saniona AB | 1.40 |
Additional Tools for Scandion Stock Analysis
When running Scandion Oncology's price analysis, check to measure Scandion Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scandion Oncology is operating at the current time. Most of Scandion Oncology's value examination focuses on studying past and present price action to predict the probability of Scandion Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scandion Oncology's price. Additionally, you may evaluate how the addition of Scandion Oncology to your portfolios can decrease your overall portfolio volatility.